Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of NYX-783 in Subjects With Post-Traumatic Stress Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* A primary diagnosis of PTSD \[Post Traumatic Stress Disorder, according to DSM-5 (Diagnostic and Statistical Manual of Mental Disorders)\] with the primary traumatic event occurring ≥12 months prior to screening.~* PCL-5 (PTSD Checklist for DSM-5) ≥38 at screening.~* CAPS-5 (Clinician-Administered PTSD Scale for DSM-5) total score ≥30 at screening.~Exclusion Criteria:~* Complex PTSD.~* Trauma focused psychotherapies.~* Primary traumatic event occurred prior to 2001.~* Primary traumatic event was followed by further major traumatic life episodes.~* Other psychiatric disorders that is the primary focus of treatment or followed/worsened since exposure to the trauma (except for major depressive disorder or anxiety disorders that followed exposure to the trauma or an anxiety disorder that showed a worsening after trauma)~* Current use of medications with primarily central nervous system activities~* Other clinically significant medical histories that may interfere with completing the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): None
- NYX-783 Low Dose (10 mg QD) (Type: EXPERIMENTAL): None
- NYX-783 High Dose (50 mg QD) (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).